COVID-19 İmmünolojisi

Emrah Salman

doi:10.37609/akya.2660

Yazarlar

Emrah Salman

DOI: https://doi.org/10.37609/akya.2660.c11788

Özet

SARS-CoV-2'ye karşı oluşan doğal ve kazanılmış bağışıklık yanıtı, enfeksiyonun önlenmesi ve kontrol altına alınmasında önemlidir. SARS-CoV-2 enfeksiyonunda virüse karşı inflamatuvar yanıt yoğun olduğu durumlarda pro-inflamatuvar sitokinler aşırı üretilir ve sitokin fırtınası olarak bilinen bu durum akut respiratuvar distres sendromu ve çoklu organ yetmezliğine yol açar. Aşılama ve doğal enfeksiyon prevalansı dünya çapında arttıkça, primer veya reenfeksiyon riskini tahmin eden yaklaşımlara olan ilgi artmaktadır. Viral varyantların ortaya çıkmasıyla tetiklenen art arda gelen enfeksiyon dalgaları mevcutken, iyileşen hastaların bir alt grubunda, uzamış COVID-19 olarak adlandırılan uzun süreli hastalık semptomları giderek artan şekilde tanınmaktadır.

Referanslar

Diamond MS, Kanneganti T-D. Innate immunity: the first line of defense against SARS-CoV-2. Nature immunology 2022;23(2):165-176. doi: 10.1038/s41590-021-01091-0.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-80.doi: 10.1016/j.cell.2020.02.052.

Cantuti-Castelvetri L, Ojha R, Pedro LD, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science 2020;370(6518):856-860.doi: 10.1126/science.abd2985

Bayati A, Kumar R, Francis V, et al. SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis. Journal of biological chemistry 2021;296:100306.doi: 10.1016/j.jbc.2021.100306.

Lee S, Channappanavar R, Kanneganti T-D. Coronaviruses: innate immunity, inflammasome activation, inflammatory cell death, and cytokines. Trends in immunology 2020;41(12):1083-1099.doi: 10.1016/j.it.2020.10.005.

Kanneganti T-D. Intracellular innate immune receptors: Life inside the cell. Immunological reviews 2020;297(1):5.doi: 10.1111/imr.12912.doi: 10.1111/imr.12912.

Akira S, Takeda K. Toll-like receptor signalling. Nature reviews immunology 2004;4(7):499-511.doi: 10.1038/nri1391.

Zheng M, Karki R, Williams EP, et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nature immunology 2021;22(7):829-838.doi: 10.1038/s41590-021-00937-x.

9. Yang D-M, Geng T-T, Harrison AG, et al. Differential roles of RIG-I like receptors in SARS-CoV-2 infection. Military medical research 2021;8(1):1-3.doi: 10.1186/s40779-021-00340-5.

Christgen S, Kanneganti T-D. Inflammasomes and the fine line between defense and disease. Current opinion in immunology 2020;62:39-44.doi: 10.1016/j.coi.2019.11.007.

Laing AG, Lorenc A, Del Molino Del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nature medicine 2020;26(10):1623-1635.doi: 10.1038/s41591-020-1038-6.

Siu K-L, Yuen K-S, Castaño-Rodriguez C, et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. The FASEB Journal 2019;33(8):8865-8877.doi: 10.1096/fj.201802418R

Franz KM, Neidermyer WJ, Tan Y-J, et al. STING-dependent translation inhibition restricts RNA virus replication. Proceedings of the National academy of sciences 2018;115(9):2058-2067.doi: 10.1073/pnas.1716937115.

Singh KK, Chaubey G, Chen JY, et al. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. American journal of physiology-cell physiology 2020;319(2), 258–267.doi: 10.1152/ajpcell.00224.2020.

Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell 2021;184(7):1671-1692.doi: 10.1016/j.cell.2021.02.029.

Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020;369(6504):718-724.doi: 10.1126/science.abc6027.

Burke SJ, Batdorf HM, Burk DH, et al. Pancreatic deletion of the interleukin-1 receptor disrupts whole body glucose homeostasis and promotes islet β-cell de-differentiation. Molecular metabolism 2018;14:95-107.doi: 10.1016/j.molmet.2018.06.003.

Karki R, Sharma BR, Tuladhar S, et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 2021;184(1):149-168.doi: 10.1016/j.cell.2020.11.025.

Malireddi R, Karki R, Sundaram B, et al. Inflammatory cell death, PANoptosis, mediated by cytokines in diverse cancer lineages inhibits tumor growth. Immunohorizons 2021;5(7):568-580.doi: 10.4049/immunohorizons.2100059.

Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. New England journal of medicine 2020;383(2):120-128.doi: 10.1056/NEJMoa2015432.

Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation 2020;142(5):429-436.doi: 10.1161/CIRCULATIONAHA.120.048360.

Poor HD. Pulmonary thrombosis and thromboembolism in COVID-19. Chest 2021;160(4):1471-1480. doi: 10.1016/j.chest.2021.06.016.

Kaneko N, Kuo H-H, Boucau J, et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell 2020;183(1):143-57.doi: 10.1016/j.cell.2020.08.025.

Bhardwaj A, Sapra L, Saini C, et al. COVID-19: immunology, immunopathogenesis and potential therapies. International reviews of immunology 2022;41(2):171-206.doi: 10.1080/08830185.2021.1883600.

Narayanan K, Huang C, Lokugamage K, et al. Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. Journal of virology 2008;82(9):4471-4479.doi: 10.1128/JVI.02472-07.

Kindler E, Thiel V, Weber F. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Advances in virus research 2016;96:219-243.doi: 10.1016/bs.aivir.2016.08.006.

Sun L, Xing Y, Chen X, et al. Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PloS one 2012;7(2):e30802.doi: 10.1371/journal.pone.0030802.

Cheung CY, Poon LL, Ng IH, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. Journal of virology 2005;79(12):7819-7826.doi: 10.1128/JVI.79.12.7819-7826.2005.

Channappanavar R, Perlman S, editors. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in immunopathology 2017;39(5), 529–539. doi: 10.1007/s00281-017-0629-x.

Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Science immunology 2020;5(49):eabd7114.doi: 10.1126/sciimmunol.abd7114.

Notarbartolo S, Ranzani V, Bandera A, et al. Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19. Science immunology 2021;6(62):eabg5021.doi: 10.1126/sciimmunol.abg5021.

Russell CD, Unger SA, Walton M, et al. The human immune response to respiratory syncytial virus infection. Clinical microbiology reviews 2017;30(2):481-502.doi: 10.1128/CMR.00090-16.

Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Frontiers in immunology 2020;11:827.doi: 10.3389/fimmu.2020.00827.

Graham MB, Braciale VL, Braciale TJ. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. The Journal of experimental medicine 1994;180(4):1273-1282.doi: 10.1084/jem.180.4.1273.

Su Y, Chen D, Yuan D, et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell 2020;183(6):1479-1495.doi: 10.1016/j.cell.2020.10.037.

Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 2020;369(6508):eabc8511.doi: 10.1126/science.abc8511.

Rha M-S, Jeong HW, Ko J-H, et al. PD-1-expressing SARS-CoV-2-specific CD8+ T cells are not exhausted, but functional in patients with COVID-19. Immunity 2021;54(1):44-52.doi: 10.1016/j.immuni.2020.12.002.

Shen-Orr SS, Furman D, Kidd BA, et al. Defective signaling in the JAK-STAT pathway tracks with chronic inflammation and cardiovascular risk in aging humans. Cell systems 2016;3(4):374-384. doi: 10.1016/j.cels.2016.09.009.

Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. Journal of experimental medicine 2021;218(5): e20202617. doi: 10.1084/jem.20202617.

Hillaire M, Rimmelzwaan G, Kreijtz J. Clearance of influenza virus infections by T cells: risk of collateral damage? Current opinion in virology 2013;3(4):430-437.doi: 10.1016/j.coviro.2013.05.002.

Song J-W, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nature communications 2020;11(1):3410.doi: 10.1038/s41467-020-17240-2

Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature immunology 2020;21(11):1336-1345.doi: 10.1038/s41590-020-0782-6.

Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell reports medicine 2021;2(2):100204.doi: 10.1016/j.xcrm.2021.100204.

Stephenson E, Reynolds G, Botting RA, et al. Single-cell multi-omics analysis of the immune response in COVID-19. Nature medicine 2021;27(5):904-916.doi: 10.1038/s41591-021-01329-2

Grifoni A, Sidney J, Vita R, et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. Cell host & microbe 2021;29(7):1076-1092.doi: 10.1016/j.chom.2021.05.010.

Low JS, Vaqueirinho D, Mele F, et al. Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science 2021;372(6548):1336-1341.doi: 10.1126/science.abg8985.

Weingarten-Gabbay S, Klaeger S, Sarkizova S, et al. Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs. Cell 2021;184(15):3962-3980.doi: 10.1016/j.cell.2021.05.046.

Peng Y, Felce SL, Dong D, et al. An immunodominant NP105–113-B* 07: 02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nature immunology 2022;23(1):50-61.doi: 10.1038/s41590-021-01084-z.

Yang JR, Deng DT, Wu N, et al. Persistent viral RNA positivity during the recovery period of a patient with SARS‐CoV‐2 infection. Journal of medical virology 2020;92(9):1681-1683.doi: 10.1002/jmv.25940.

Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature communications 2021;12(1):1162.doi: 10.1038/s41467-021-21444-5

Cohen KW, Linderman SL, Moodie Z, et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Reports Medicine 2021;2(7):100354.doi: 10.1016/j.xcrm.2021.100354.

Jung JH, Rha M-S, Sa M, et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nature communications 2021;12(1):4043.doi: 10.1038/s41467-021-24377-1.

Adamo S, Michler J, Zurbuchen Y, et al. Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection. Nature 2022;602(7895):148-155.doi: 10.1038/s41586-021-04280-x.

Grau-Expósito J, Sánchez-Gaona N, Massana N, et al. Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nature communications 2021;12(1):3010.doi: 10.1038/s41467-021-23333-3.

da Silva Antunes R, Pallikkuth S, Williams E, et al. Differential T-cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers. The Journal of infectious diseases 2021;224(1):70-80.doi: 10.1093/infdis/jiab176.

Rowland-Jones SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Current opinion in immunology 1995;7(4):448-455.doi: 10.1016/0952-7915(95)80087-5.

Swadling L, Diniz MO, Schmidt NM, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature 2022;601(7891):110-117.doi: 10.1038/s41586-021-04186-8.

Zeng C, Evans JP, King T, et al. SARS-CoV-2 spreads through cell-to-cell transmission. Proceedings of the National academy of sciences 2022;119(1):e2111400119.doi: 10.1073/pnas.211140011.

Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003;299(5613):1713-1716. doi: 10.1126/science.1080115.

Bange EM, Han NA, Wileyto P, et al. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature medicine 2021;27(7):1280-1289.doi: 10.1038/s41591-021-01386-7.

Moss P. The T cell immune response against SARS-CoV-2. Nature immunology 2022;23(2):186-193.doi: 10.1038/s41590-021-01122-w.

Tregoning JS, Flight KE, Higham SL, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature reviews immunology 2021;21(10):626-636.doi: 10.1038/s41577-021-00592-1.

Oberhardt V, Luxenburger H, Kemming J, et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature 2021;597(7875):268-273.doi: 10.1038/s41586-021-03841-4.

Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021;595(7868):572-577.doi: 10.1038/s41586-021-03653-6.

Skelly DT, Harding AC, Gilbert-Jaramillo J, et al. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature communications 2021;12(1):5061.doi: 10.1038/s41467-021-25167-5

Parry H, Bruton R, Tut G, et al. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. The Lancet healthy longevity 2021;2(9):554-560.doi: 10.1016/S2666-7568(21)00169-0.

Stuart AS, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet 2022;399(10319):36-49.doi: 10.1016/S0140-6736(21)02718-5.

Shaw RH, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. The Lancet 2021;397(10289):2043-2046.doi: 10.1016/S0140-6736(21)01115-6.

Heitmann JS, Bilich T, Tandler C, et al. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature 2022;601(7894):617-622.doi: 10.1038/s41586-021-04232-5.

Mazzoni A, Di Lauria N, Maggi L, et al. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. The Journal of clinical investigation 2021;131(12): e149150. doi: 10.1172/JCI149150.

Rice A, Verma M, Shin A, et al. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. Scientific reports 2021;11(1):14917.doi: 10.1038/s41598-021-94364-5.

Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nature reviews immunology 2021;21(6):395-404.doi: 10.1038/s41577-021-00550-x.

Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021;39(32):4423-4428.doi: 10.1016/j.vaccine.2021.05.063.

Nathan A, Rossin EJ, Kaseke C, et al. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell 2021;184(17):4401-4413.doi: 10.1016/j.cell.2021.06.029.

Shoukat MS, Foers AD, Woodmansey S, et al. Use of machine learning to identify a T cell response to SARS-CoV-2. Cell Reports Medicine 2021;2(2):100192.doi: 10.1016/j.xcrm.2021.100192.

Elsner RA, Shlomchik MJ. Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity. Immunity 2020;53(6):1136-1150.doi: 10.1016/j.immuni.2020.11.006.

Palm A-KE, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Frontiers in immunology 2019;10:1787.doi: 10.3389/fimmu.2019.01787.

Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature medicine 2020;26(6):845-848.doi: 10.1038/s41591-020-0897-1.

Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 2020;584(7821):437-442.doi: 10.1038/s41586-020-2456-9.

Klassen SA, Senefeld JW, Johnson PW, et al., editors. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo clinic proceedings 2021;96(5):1262-1275.doi: 10.1016/j.mayocp.2021.02.008.

Abani O, Abbas A, Abbas F, et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet 2021;397(10289):2049-2059.doi: 10.1016/S0140-6736(21)00897-7.

Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature medicine 2021;27(7):1205-1211.doi: 10.1038/s41591-021-01377-8.

Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020;370(6521):1227-1230.doi: 10.1126/science.abd7728.

Stamatatos L, Czartoski J, Wan Y-H, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science 2021;372(6549):1413-1418.doi: 10.1126/science.abg9175.

Wang C, van Haperen R, Gutiérrez-Álvarez J, et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nature communication. 2021;12(1):1715.doi: 10.1038/s41467-021-21968-w.

Isho B, Abe KT, Zuo M, et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Science immunology 2020;5(52):eabe5511.doi: 10.1126/sciimmunol.abe5511.

Woodruff MC, Ramonell RP, Nguyen DC, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nature immunology 2020;21(12):1506-1516.doi: 10.1038/s41590-020-00814-z.

Sakharkar M, Rappazzo CG, Wieland-Alter WF, et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science immunology 2021;6(56):eabg6916.doi: 10.1126/sciimmunol.abg6916.

Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nature reviews immunology 2021;21(4):245-256.doi: 10.1038/s41577-021-00522-1.

Chen Y, Zuiani A, Fischinger S, et al. Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. Cell 2020;183(6):1496-1507.doi: 10.1016/j.cell.2020.10.051.

Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature medicine 2020;26(8):1200-1204.doi: 10.1038/s41591-020-0965-6.

Russell MW, Moldoveanu Z, Ogra PL, et al. Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection. Frontiers in immunology 2020;11:611337.doi: 10.3389/fimmu.2020.611337.

Wang Z, Lorenzi JC, Muecksch F, et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science translational medicine 2021;13(577):eabf1555.doi: 10.1126/scitranslmed.abf1555.

Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. Journal of Allergy and Clinical immunology 2021;147(2):545-557.doi: 10.1016/j.jaci.2020.10.040.

Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Science translational medicine 2021;13(577):eabd2223.doi: 10.1126/scitranslmed.abd2223.

Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nature reviews microbiology 2021;19(3):141-154.doi: 10.1038/s41579-020-00459-7.

Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574.doi: 10.1016/S0140-6736(20)30251-8.

Dugan HL, Stamper CT, Li L, et al. Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity 2021;54(6):1290-1303.doi: 10.1016/j.immuni.2021.05.001.

Che X-y, Qiu L-w, Liao Z-y, et al. Antigenic cross-reactivity between severe acute respiratory syndrome—associated coronavirus and human coronaviruses 229E and OC43. Journal of infectious disease 2005;191(12):2033-2037.doi: 10.1086/430355.

Zhu Y, Yu D, Han Y, et al. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Science advances 2020;6(45):eabc9999.doi: 10.1126/sciadv.abc9999.

Anderson EM, Goodwin EC, Verma A, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell 2021;184(7):1858-1864.doi: 10.1016/j.cell.2021.02.010.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.doi: 10.1016/S0140-6736(20)30183-5.

Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 2020;584(7819):115-119.doi: 10.1038/s41586-020-2380-z.

Gaebler C, Wang Z, Lorenzi JC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021;591(7851):639-644.doi: 10.1038/s41586-021-03207-w.

Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature 2021;595(7867):421-425.doi: 10.1038/s41586-021-03647-4.

Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nature reviews immunology 2020;20(9):529-536.doi: 10.1038/s41577-020-0402-6.

Poon MM, Rybkina K, Kato Y, et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Science immunology 2021;6(65):eabl9105.doi: 10.1126/sciimmunol.abl9105.

Pinto D, Sauer MM, Czudnochowski N, et al. Broad betacoronavirus neutralization by a stem helix–specific human antibody. Science 2021;373(6559):1109-1116.doi: 10.1126/science.abj3321.

Ge J, Wang R, Ju B, et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nature communications 2021;12(1):250.doi: 10.1038/s41467-020-20501-9.

McCallum M, Czudnochowski N, Rosen LE, et al. Structural basis of SARS-CoV-2 Omikron immune evasion and receptor engagement. Science 2022;375(6583):864-868.doi: 10.1126/science.abn8652.

Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omikron variant of SARS-CoV-2. Nature 2022;602(7898):676-681.doi: 10.1038/s41586-021-04388-0.

McCallum M, De Marco A, Lempp FA, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 2021;184(9):2332-2347.doi: 10.1016/j.cell.2021.03.028.

Winkler ES, Gilchuk P, Yu J, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell 2021;184(7):1804-1820.doi: 10.1016/j.cell.2021.02.026.

Chen X, Rostad CA, Anderson LJ, et al. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein. Virology 2021;559:1-9.doi: 10.1016/j.virol.2021.03.009.

Lee WS, Selva KJ, Davis SK, et al. Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell reports medicine.2021;2(6):100296.doi: 10.1016/j.xcrm.2021.100296.

Junqueira C, Crespo Â, Ranjbar S, et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 2022;606(7914):576-584.doi: 10.1038/s41586-022-04702-4.

Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nature reviews immunology 2020;20(6):339-341.doi: 10.1038/s41577-020-0321-6.

Amanat F, Thapa M, Lei T, et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 2021;184(15):3936-3948.doi: 10.1016/j.cell.2021.06.005.

Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nature reviews immunology 2021;21(2):73-82.doi: 10.1038/s41577-020-00480-0.

Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 2020;396(10249):479-488.doi: 10.1016/S0140-6736(20)31605-6.

Yin W, Xu Y, Xu P, et al. Structures of the Omikron spike trimer with ACE2 and an anti-Omikron antibody. Science 2022;375(6584):1048-1053.doi: 10.1126/science.abn8863.

Wang K, Jia Z, Bao L, et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature 2022;603(7903):919-925.doi: 10.1038/s41586-022-04466-x.

Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 Omikron variant neutralization after mRNA-1273 booster vaccination. New England journal of medicine 2022;386(11):1088-1091.doi: 10.1056/NEJMc2119912

Munro AP, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. The Lancet 2021;398(10318):2258-2276.doi: 10.1016/S0140-6736(21)02717-3.

Atmar RL, Lyke KE, Deming ME, et al. Homologous and heterologous Covid-19 booster vaccinations. New England journal of medicine 2022;386(11):1046-1057.doi: 10.1056/NEJMoa2116414

Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omikron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses. Cell 2022;185(3):467-484.doi: 10.1016/j.cell.2021.12.046.

Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omikron. Nature 2022;602(7898):682-688.doi: 10.1038/s41586-022-04399-5.

Gagne M, Moliva JI, Foulds KE, et al. mRNA-1273 or mRNA-Omikron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omikron. Cell 2022;185(9):1556-1571.doi: 10.1016/j.cell.2022.03.038.

Saunders KO, Lee E, Parks R, et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 2021;594(7864):553-559.doi: 10.1038/s41586-021-03594-0.

Walls AC, Miranda MC, Schäfer A, et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 2021;184(21):5432-5447.doi: 10.1016/j.cell.2021.09.015.

Cohen AA, Gnanapragasam PN, Lee YE, et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 2021;371(6530):735-741.doi: 10.1126/science.abf6840.

Wuertz KM, Barkei EK, Chen W-H, et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. NPJ Vaccines 2021;6(1):129.doi: 10.1038/s41541-021-00392-7.

Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 2022;185(10):1728-1744.doi: 10.1016/j.cell.2022.03.044.

Tan C-W, Chia W-N, Young BE, et al. Pan-sarbecovirus neutralizing antibodies in BNT162b2-immunized SARS-CoV-1 survivors. New England journal of medicine 2021;385(15):1401-1406. doi: 10.1056/NEJMoa2108453.

Shah W, Hillman T, Playford ED, et al. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ 2021;372: n136.doi: 10.1136/bmj.n136.

Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC neurology 2011;11(1):1-7.doi: 10.1186/1471-2377-11-37.

Ngai JC, Ko FW, Ng SS, et al. The long‐term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010;15(3):543-550.doi: 10.1111/j.1440-1843.2010.01720.x.

Ong KC, Ng A-K, Lee L-U, et al. Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. European respiratory journal 2004;24(3):436-442.doi: 10.1183/09031936.04.00007104

Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian journal of radiology and imaging 2017;27(03):342-349.doi: 10.4103/ijri.IJRI_469_16.

Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nature immunology 2022;23(2):194-202.doi: 10.1038/s41590-021-01104-y.

Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA, 324(6), 603–605.doi: 10.1001/jama.2020.12603.

Han X, Fan Y, Alwalid O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;299(1):177-186.doi: 10.1148/radiol.2021203153.

Chopra V, Flanders SA, O’Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Annals of internal medicine 2021;174(4):576-578.doi: 10.7326/M20-5661.

Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet 2021;397(10270):220-232.doi: 10.1016/S0140-6736(20)32656-8.

Manolis TA, Apostolopoulos EJ, Manolis AA, et al. COVID-19 infection: a neuropsychiatric perspective. The Journal of neuropsychiatry and clinical neurosciences 2021;33(4):266-279.doi: 10.1176/appi.neuropsych.20110277.

Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. Journal of infection 2020;81(6):4-6.doi: 10.1016/j.jinf.2020.08.029.

Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 2021;76(4):399-401.doi: 10.1136/thoraxjnl-2020-215818.

Heneka MT, Golenbock D, Latz E, et al. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimer's research & therapy 2020;12:1-3.doi: 10.1186/s13195-020-00640-3.

Taquet M, Luciano S, Geddes JR, et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet psychiatry 2021;8(2):130-140.doi: 10.1016/S2215-0366(20)30462-4.

Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clinical microbiology and infection 2021;27(2):258-263.doi: 10.1016/j.cmi.2020.09.052.

Dennis A, Wamil M, Alberts J, et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ open 2021;11(3):e048391.doi: 10.1136/bmjopen-2020-048391.

Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet hematology 2020;7(6):438-440.doi: 10.1016/S2352-3026(20)30145-9.

Suárez-Fariñas M, Tokuyama M, Wei G, et al. Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2–related disease. Gastroenterology 2021;160(1):287-301.doi: 10.1053/j.gastro.2020.09.029.

Mao R, Qiu Y, He J-S, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The lancet gastroenterology & hepatology 2020;5(7):667-678.doi: 10.1016/S2468-1253(20)30126-6.

Weng J, Li Y, Li J, et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. The Lancet gastroenterology & hepatology 2021;6(5):344-346.doi: 10.1016/S2468-1253(21)00076-5.

Yang J-K, Lin S-S, Ji X-J, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta diabetologica 2010;47:193-199.doi: 10.1007/s00592-009-0109-4.

Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in Covid-19. New England journal of medicine 2020;383(8):789-790.doi: 10.1056/NEJMc2018688

Montefusco L, Ben Nasr M, D’Addio F, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nature metabolism 2021;3(6):774-785.doi: 10.1038/s42255-021-00407-6.

Brancatella A, Ricci D, Viola N, et al. Subacute thyroiditis after Sars-COV-2 infection. The journal of clinical endocrinology & metabolism 2020;105(7):2367-2370.doi: 10.1210/clinem/dgaa276.

Tee LY, Harjanto S, Rosario BH. COVID-19 complicated by Hashimoto's thyroiditis. Singapore medical journal 2020;62(5):265.doi: 10.11622/smedj.2020106.

Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. Journal of endocrinological investigation 2020;43:1527-1528.doi: 10.1007/s40618-020-01366-7.

Stevens JS, King KL, Robbins-Juarez SY, et al. High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS one 2020;15(12):e0244131. doi: 10.1371/journal.pone.0244131.

Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries. Journal of the American academy of dermatology 2020;83(4):1118-1129.doi: 10.1016/j.jaad.2020.06.1016.

Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature immunology 2022;23(2):210-216.doi: 10.1038/s41590-021-01113-x.

Chun HJ, Coutavas E, Pine AB, et al. Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection. JCI Insight 2021;6(14):e148476.doi: 10.1172/jci.insight.148476.

Bost P, Giladi A, Liu Y, et al. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell 2020;181(7):1475-1488. doi: 10.1016/j.cell.2020.05.006.

Schneider C, Nobs SP, Kurrer M, et al. Induction of the nuclear receptor PPAR-γ by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nature immunology 2014;15(11):1026-1037.doi: 10.1038/ni.3005.

Ziegler CG, Allon SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020;181(5):1016-1035.doi: 10.1016/j.cell.2020.04.035.

Ravetch JV, Kinet J-P. Fc receptors. Annual review of immunology 1991;9(1):457-492. doi: 10.1146/annurev.iy.09.040191.002325.

Chakraborty S, Gonzalez J, Edwards K, et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nature immunology 2021;22(1):67-73.doi: 10.1038/s41590-020-00828-7.

Barzilai O, Ram M, Shoenfeld Y. Viral infection can induce the production of autoantibodies. Current opinion in rheumatology 2007;19(6):636-643.doi: 10.1097/BOR.0b013e3282f0ad25

Fujinami RS, von Herrath MG, Christen U, et al. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clinical microbiology reviews 2006;19(1):80-94. doi: 10.1128/CMR.19.1.80-94.2006.

Ohashi PS, Oehen S, Buerki K, et al. Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65(2):305-317.doi: 10.1016/0092-8674(91)90164-T.